Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
24/05/2024 | 13:30 | PR Newswire (US) | YS Biopharma Announces Name Change to LakeShore Biopharma | NASDAQ:YS | YS Biopharma Company Ltd |
21/05/2024 | 22:15 | PR Newswire (US) | YS Biopharma Announces Results of Extraordinary General Meeting | NASDAQ:YS | YS Biopharma Company Ltd |
07/05/2024 | 22:20 | PR Newswire (US) | YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer | NASDAQ:YS | YS Biopharma Company Ltd |
29/04/2024 | 14:00 | PR Newswire (US) | YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule | NASDAQ:YS | YS Biopharma Company Ltd |
19/04/2024 | 13:00 | PR Newswire (US) | YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 | NASDAQ:YS | YS Biopharma Company Ltd |
18/04/2024 | 14:00 | PR Newswire (US) | YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine | NASDAQ:YS | YS Biopharma Company Ltd |
16/04/2024 | 14:00 | PR Newswire (US) | YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 | NASDAQ:YS | YS Biopharma Company Ltd |
09/04/2024 | 14:00 | PR Newswire (US) | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine | NASDAQ:YS | YS Biopharma Company Ltd |
03/04/2024 | 14:00 | PR Newswire (US) | YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility | NASDAQ:YS | YS Biopharma Company Ltd |
05/03/2024 | 14:00 | PR Newswire (US) | YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries | NASDAQ:YS | YS Biopharma Company Ltd |
22/02/2024 | 23:00 | PR Newswire (US) | YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 | NASDAQ:YS | YS Biopharma Company Ltd |
18/02/2024 | 10:30 | PR Newswire (US) | /C O R R E C T I O N -- YS Biopharma Co., Ltd./ | NASDAQ:YS | YS Biopharma Company Ltd |
17/02/2024 | 02:20 | PR Newswire (US) | YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting | NASDAQ:YS | YS Biopharma Company Ltd |
14/02/2024 | 14:00 | PR Newswire (US) | YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance | NASDAQ:YS | YS Biopharma Company Ltd |
14/02/2024 | 13:50 | PR Newswire (US) | YS Biopharma Announces Appointment of New Directors | NASDAQ:YS | YS Biopharma Company Ltd |
12/02/2024 | 14:50 | PR Newswire (US) | YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. | NASDAQ:YS | YS Biopharma Company Ltd |
09/02/2024 | 12:30 | PR Newswire (US) | YS Biopharma Announces US$40 Million Private Placement Financing | NASDAQ:YS | YS Biopharma Company Ltd |
09/02/2024 | 00:10 | PR Newswire (US) | Shareholders of YS Biopharma Announce an Extraordinary General Meeting | NASDAQ:YS | YS Biopharma Company Ltd |
22/01/2024 | 23:00 | PR Newswire (US) | YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 | NASDAQ:YS | YS Biopharma Company Ltd |
08/01/2024 | 14:00 | PR Newswire (US) | YS Biopharma Announces Changes to its Board Committees | NASDAQ:YS | YS Biopharma Company Ltd |
20/12/2023 | 22:30 | PR Newswire (US) | YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting | NASDAQ:YS | YS Biopharma Company Ltd |
20/12/2023 | 14:56 | PR Newswire (US) | YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023 | NASDAQ:YS | YS Biopharma Company Ltd |
14/11/2023 | 14:30 | PR Newswire (US) | Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target | NASDAQ:YS | YS Biopharma Company Ltd |
31/10/2023 | 13:30 | PR Newswire (US) | YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine | NASDAQ:YS | YS Biopharma Company Ltd |
26/10/2023 | 14:30 | PR Newswire (US) | YS Biopharma Announces Receipt of Nasdaq Notice | NASDAQ:YS | YS Biopharma Company Ltd |
26/09/2023 | 14:30 | PR Newswire (US) | YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine | NASDAQ:YS | YS Biopharma Company Ltd |
15/09/2023 | 14:30 | PR Newswire (US) | YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection | NASDAQ:YS | YS Biopharma Company Ltd |
05/09/2023 | 14:30 | PR Newswire (US) | YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference | NASDAQ:YS | YS Biopharma Company Ltd |
24/08/2023 | 22:15 | PR Newswire (US) | YS Biopharma Announces Purchase of Shares by Company Officers | NASDAQ:YS | YS Biopharma Company Ltd |
15/08/2023 | 23:00 | PR Newswire (US) | YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 | NASDAQ:YS | YS Biopharma Company Ltd |